Low platelet count reduces subsequent complete remission rate despite marrow with <5% blasts after AML induction therapy
Xiaodong Chen(Pacific Northwest National Laboratory), Elihu H. Estey(University of Washington), Hu Xie(Fred Hutch Cancer Center), Vicky Sandhu(Fred Hutch Cancer Center), John M. Pagel(University of Washington), Pamela S. Becker(City Of Hope National Medical Center), Janis L. Abkowitz(University of Washington), Laura F. Newell(University of Washington), Paul C. Hendrie(University of Washington), F R Appelbaum(City Of Hope National Medical Center), Roland B. Walter(Rafael Advanced Defense Systems (Israel))
Cited by 8
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
|Journal of Clinical Oncology|2003|2.7k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k